Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Completed 2Active not recruiting 2

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 4Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

Melanoma 18Prostatic Neoplasms 6Carcinoma, Renal Cell 5Uveal Melanoma 4Sarcoma 4Histiocytoma, Malignant Fibrous 4Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Vulvar Neoplasms 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Urethral Neoplasms 2Thyroid Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Myelodysplastic Syndromes 2Liposarcoma 2Leukemia 2Gastrointestinal Stromal Tumors 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Carcinoma, Endometrioid 2Bone Neoplasms 2Vaginal Neoplasms 1Urogenital Neoplasms 1Ureteral Neoplasms 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1

Interventions

Doxorubicin 62Ifosfamide 39Gemcitabine 29Radiotherapy 27Filgrastim 27Cyclophosphamide 26Docetaxel 19Vincristine 18pembrolizumab 17Etoposide 17pazopanib 16Cisplatin 16Nivolumab 15Trabectedin 14apatinib 13Magnetic Resonance Spectroscopy 13Carboplatin 12Irinotecan 11Bevacizumab 11Temozolomide 10Sirolimus 10camrelizumab 9anlotinib 9Surgical Procedures, Operative 9Sorafenib 9Paclitaxel 9Ipilimumab 9Injections 9Dactinomycin 9Topotecan 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Sarcoma × CTLA-4 Antigen × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT05836571 2026-04-21

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
66 enrolled
Sarcoma

Sarcoma, Histiocytoma, Malignant Fibrous

NCT04118166 2023-12-12

Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma

Stanford University

Phase 2 Completed
30 enrolled 9 charts
Sarcoma

Sarcoma

NCT02500797 2023-10-17

Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
164 enrolled 22 charts
Sarcoma

Bone Neoplasms, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡